Aura Biosciences, Inc.

Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Aura Biosciences granted inducement equity awards to three newly appointed C-level executives: Chief Regulatory and Quality Officer Dr. Erica Kratz, Chief Operating Officer Dr. Susan Abu-Absi, and Chief People Officer Julie Person. The awards consist of options to purchase an aggregate of 676,991 shares and restricted stock units for 343,009 shares, with an exercise price of $7.43 per share matching the September 1 closing price. This leadership expansion supports the company as it advances the fully enrolled Phase 3 registration study of its ocular cancer therapy bel-sar.

•2mo ago

Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors

Aura Biosciences has appointed Jeremy Bender, Ph.D., M.B.A., to its Board of Directors, adding significant expertise in late-stage development and commercialization. Dr. Bender previously served as CEO of Day One Biopharmaceuticals, leading the company through its approval and launch of OJEMDA and its subsequent $2.5 billion acquisition by Servier. The appointment comes as Aura advances its lead candidate bel-sar through the Phase 3 CoMpass trial for early choroidal melanoma.

•3mo ago

Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights

Aura Biosciences reported a net loss of $33.7 million for the first quarter of 2026, compared to $27.5 million in the same period last year. The company completed an oversubscribed $280.8 million equity financing, which, after expenses, provided approximately $280.8 million in net proceeds. This strengthens the balance sheet and extends the cash runway into the second half of 2028. Natalie Holles was appointed as the new CEO and President, effective April 30, 2026, succeeding Elisabet de los Pinos, Ph.D., who stepped down from her roles. The Phase 3 CoMpass trial for bel-sar in early choroidal melanoma is advancing toward enrollment completion, with topline data expected in the second half of 2027.

•5mo ago